This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Wall Street analysts downgraded Rollins, Yum Brands, Alkami Technology, VICI Properties and Safehold, cutting targets for Rollins and Alkami.
Stocks · News reference
Wave Life Sciences Starts Phase 2a Clinical Study Of WVE-007 To Treat Obesity
Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the initiation of its Phase 2a clinical
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wave Life Sciences shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral rating. The company also announced the initiation of its Phase 2a clinical trial evaluating WVE-007 in combination with tirzepatide in adults living with obesity.
This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.
JP Morgan Downgrades Wave Life Sciences to Neutral
JP Morgan analyst Tessa Romero downgrades Wave Life Sciences (NASDAQ:WVE) from Overweight to Neutral.